Medullary Thyroid Cancer - Pipeline Review, H1 2012
Global Markets Direct
January 23, 2012 69 Pages - SKU: GMD6775958
|
|
Medullary Thyroid Cancer - Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Medullary Thyroid Cancer - Pipeline Review, H1 2012', provides an overview of the Medullary Thyroid Cancer therapeutic pipeline. This report provides information on the therapeutic development for Medullary Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Medullary Thyroid Cancer. 'Medullary Thyroid Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Medullary Thyroid Cancer.
- A review of the Medullary Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Medullary Thyroid Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Medullary Thyroid Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Medullary Thyroid Cancer pipeline depth and focus of Medullary Thyroid Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
|
- Introduction
- Global Markets Direct Report Coverage
- Medullary Thyroid Cancer Overview
- Therapeutics Development
- An Overview of Pipeline Products for Medullary Thyroid Cancer
- Medullary Thyroid Cancer Therapeutics under Development by Companies
- Medullary Thyroid Cancer Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Medullary Thyroid Cancer Therapeutics - Products under Development by Companies
- Medullary Thyroid Cancer Therapeutics - Products under Investigation by Universities/Institutes
- Companies Involved in Medullary Thyroid Cancer Therapeutics Development
- Novartis AG
- Exelixis, Inc.
- Globeimmune, Inc.
- Medullary Thyroid Cancer - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Afinitor - Drug Profile
- Cabozantinib - Drug Profile
- Gleevec + Dacarbazine + Xeloda - Drug Profile
- ZD6474 - Drug Profile
- GI-6207 - Drug Profile
- Gleevec - Drug Profile
- Pazopanib Hydrochloride - Drug Profile
- Tanespimycin - Drug Profile
- Lithium Carbonate - Drug Profile
- Afinitor - Drug Profile
- LBH589 - Drug Profile
- Temsirolimus + Vinorelbine Ditartrate - Drug Profile
- Aplidin - Drug Profile
- Prednisone + Thalidomide - Drug Profile
- Sorafenib Tosylate - Drug Profile
- Sunitinib - Drug Profile
- Sutent - Drug Profile
- Pasireotide LAR + Everolimus - Drug Profile
- Thalidomide - Drug Profile
- Medullary Thyroid Cancer Therapeutics - Drug Profile Updates
- Medullary Thyroid Cancer Therapeutics - Dormant Products
- Medullary Thyroid Cancer - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Medullary Thyroid Cancer, H1 2012
- Products under Development for Medullary Thyroid Cancer - Comparative Analysis, H1 2012
- Number of Products under Development by Companies, H1 2012
- Number of Products under Investigation by Universities/Institutes, H1 2012
- Comparative Analysis by Late Stage Development, H1 2012
- Comparative Analysis by Mid Clinical Stage Development, H1 2012
- Comparative Analysis by Early Clinical Stage Development, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Novartis AG, H1 2012
- Exelixis, Inc., H1 2012
- Globeimmune, Inc., H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Medullary Thyroid Cancer Therapeutics - Drug Profile Updates
- Medullary Thyroid Cancer Therapeutics - Dormant Products
- List of Figures
- Number of Products under Development for Medullary Thyroid Cancer, H1 2012
- Products under Development for Medullary Thyroid Cancer - Comparative Analysis, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Late Stage Products, H1 2012
- Mid Clinical Stage Products, H1 2012
- Early Clinical Stage Products, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Route of Administration, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Assessment by Stage and Molecule Type, H1 2012
Share this report
Other tasks Related Markets Oncology/Hematology Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
